China-based Huadong Medicine Co., Ltd (SHE: 000963) announced the first presentation of results from its Phase Ib/IIa study of DR10624, a first-in-class agonist targeting the GLP-1 receptor, GCG receptor, and FGFR1c/Klothoβ. The study focused on patients with obesity combined with hypertriglyceridemia and was presented at the EASL Congress 2025 in New Zealand.
Clinical Trial Results
DR10624 demonstrated superior efficacy in reducing liver fat content (LFC) among subjects. After 12 weeks of treatment, the relative reductions in LFC from baseline were as follows:
- 12.5 mg dose group: 51.9% reduction
- 25 mg dose group: 77.8% reduction
- 50 mg dose group: 79.0% reduction
- 75 mg dose titration group: 75.8% reduction
These results were significantly higher than the 26.3% reduction observed in the placebo group.
Key Endpoint Achievements
Regarding the clinically significant endpoint of a ≥50% relative reduction in LFC (a threshold associated with a high likelihood of histologic resolution of steatohepatitis, i.e., MASH resolution), the proportions of subjects achieving this target were:
- 12.5 mg dose group: 66.7%
- 25 mg dose group: 88.9%
- 50 mg dose group: 100%
- 75 mg dose titration group: 85.7%
These results highlight the potential of DR10624 in effectively reducing liver fat and addressing the needs of patients with obesity and hypertriglyceridemia.-Fineline Info & Tech
